$GPCR News
Last published 2d ago
- 2d agoGPCRStructure Therapeutics Inc. - EXHIBIT 99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2d agoGPCRStructure Therapeutics Reports Third Quarter 2026 Financial Results and Recent HighlightsGlobeNewswirePhase 3 ACCOMPLISH-1 and ACCOMPLISH-2 registrational clinical trials of aleniglipron (oral small molecule GLP-1 receptor agonist) enrolling; topline data expected in 2H 2028 Additional aleniglipron data expected in Q4
- 2d agoGPCRStructure Therapeutics Reports Third Quarter 2026 Financial Results and Recent HighlightsGlobeNewswire
- 1w agoGPCRStructure Therapeutics to Participate in the Jefferies Global Healthcare ConferenceGlobeNewswireSAN FRANCISCO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases,
- 3w agoGPCRStructure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2026GlobeNewswireSAN FRANCISCO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases,
- 1mo agoGPCRMorgan Stanley 24th Annual Global Healthcare Conference - STRUCTURE THERAPEUTICS INCEarnings Call TranscriptsSo, thanks for joining us. I'm Terrence Flynn, Morgan Stanley's U.S. Biopharma Analyst. For important disclosures, please see Morgan Stanleyís Research Disclosure Website at www.morganstanley.com backslash researchdisclo
- 1mo agoGPCRStructure Therapeutics - 1775259 - STRUCTURE THERAPEUTICS INCEarnings Call TranscriptsSo, thanks for joining us. I'm Terrence Flynn, Morgan Stanley's U.S. Biopharma Analyst. For important disclosures, please see Morgan Stanleyís Research Disclosure Website at www.morganstanley.com backslash researchdisclo
- 2mo agoGPCRStructure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight ManagementGlobeNewswireACCG-2671 (oral small molecule amylin receptor agonist) demonstrated a ~6-day half-life, no serious adverse events, and evidence of target engagement including up to 3.3% body weight loss in Phase 1/2a SAD clinical
- 2mo agoGPCRStructure Therapeutics to Participate in Upcoming Healthcare Investor ConferencesGlobeNewswireSAN FRANCISCO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases,
- 3mo agoGPCRStructure Therapeutics Reports Second Quarter 2026 Financial Results and Recent HighlightsGlobeNewswireFirst patients dosed in aleniglipron (oral small molecule GLP-1 receptor agonist) Phase 3 ACCOMPLISH program for chronic weight management Data from Phase 1 SAD clinical trial of ACCG-2671 (oral small molecule dual
- 5mo agoAZNNVOZLDPFROP-CH+3Drugmakers race to find a place in the next wave of obesity drugsCNBCDrugmakers are betting they can crack into the obesity drug market that Novo Nordisk and Eli Lilly currently dominate.
- 5mo agoGPCRStructure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for ObesityGlobeNewswirePublication presented concurrently with oral presentation at American Diabetes Association's 86th Scientific Sessions from ACCESS development program with aleniglipron, a once-daily oral small molecule GLP-1 receptor
- 5mo agoGPCRStructure Therapeutics Announces Participation in Upcoming Investor ConferencesGlobeNewswireSAN FRANCISCO, May 26, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases,
- 6mo agoGPCRStructure Therapeutics Reports First Quarter 2026 Financial Results and Recent HighlightsGlobeNewswireReported positive results from aleniglipron Phase 2 ACCESS II study with up to 16.3% body weight loss, demonstrating highest efficacy among oral GLP-1RAs at the 44-week time point and potentially comparable efficacy to
- 6mo agoGPCRStructure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific SessionsGlobeNewswireSAN FRANCISCO, April 27, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases,
- 7mo agoGPCRStructure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General CounselGlobeNewswireSAN FRANCISCO, April 14, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases,
- 8mo agoGPCRStructure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, AleniglipronGlobeNewswirePlacebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ACCESS II, demonstrating highest efficacy among oral GLP-1RAs and
- 8mo agoGPCRStructure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent HighlightsGlobeNewswirePositive results from the aleniglipron Phase 2 ACCESS programs in December 2025 demonstrated significant weight loss across all doses and up to 15.3% at 36 weeks Topline 44-week data from the ACCESS II study with higher
- 10mo agoGPCRStructure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of ObesityGlobeNewswireSAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases,
- 11mo agoGPCRStructure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSsGlobeNewswireSAN FRANCISCO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases,
- 11mo agoGPCRStructure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded WarrantsGlobeNewswireSAN FRANCISCO, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases,
- 11mo agoGPCRStructure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded WarrantsGlobeNewswireSAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases,
- 11mo agoGPCRStructure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, AleniglipronGlobeNewswirePlacebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight loss up to 15.3%
- 11mo agoGPCRStructure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025GlobeNewswireSAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases,
- 1y agoGPCRStructure Therapeutics Reports Third Quarter 2025 Financial Results and Recent HighlightsGlobeNewswireTopline 36-week data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for readouts by year-end 2025 Oral small molecule amylin receptor agonist (ACCG-2671) Phase 1 study
- 1y agoGPCRStructure Therapeutics Inc. (GPCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)Earnings Call Transcripts
- 1y agoGPCRStructure Therapeutics to Participate in Two Upcoming Healthcare Investor ConferencesGlobeNewswireSAN FRANCISCO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases,
- 1y agoGPCRStructure Therapeutics Reports Second Quarter 2025 Financial Results and Recent HighlightsGlobeNewswireTopline data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for year-end 2025 readouts Aleniglipron clinical development program expanded to optimize competitive
- 1y agoGPCRStructure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671GlobeNewswireSAN FRANCISCO, June 20, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases,
- 1y agoGPCRStructure Therapeutics to Participate in Multiple Upcoming Healthcare Investor ConferencesGlobeNewswireSAN FRANCISCO, May 29, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases,
- 1y agoGPCRStructure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent HighlightsGlobeNewswireAleniglipron (GSBR-1290) ACCESS and ACCESS II studies fully enrolled; topline data from both studies anticipated by year-end 2025 Oral small molecule amylin receptor agonist (ACCG-2671) Investigational New Drug
- 1y agoGPCRStructure Therapeutics to Participate in Multiple Upcoming Healthcare Investor ConferencesGlobeNewswireSAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases,
- 1y agoGPCRStructure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of ObesityGlobeNewswirePreclinical studies with ACCG-2671 demonstrate potent target engagement, robust weight loss, favorable safety profile and PK properties supportive of once-daily dosing in humans ACCG-2671 is the most advanced oral small
- 1y agoGPCRStructure Therapeutics to Participate in the Jefferies London Healthcare ConferenceGlobeNewswireSAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and
- 1y agoGPCRStructure Therapeutics Reports Third Quarter 2024 Financial Results and Recent HighlightsGlobeNewswireFirst patients dosed in Phase 2b ACCESS study of GSBR-1290 for obesity Oral small molecule amylin receptor agonist development candidate expected to be selected by the end of 2024 Strong financial position with cash,
- 1y agoGPCRStructure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for ObesityGlobeNewswirePhase 2b ACCESS study designed to evaluate multiple doses up to 120 mg of GSBR-1290 over 36 weeks Comprehensive development program also includes Phase 2 ACCESS II study to evaluate even higher doses of GSBR-1290 over
- 2y agoGPCRStructure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2024GlobeNewswireSAN FRANCISCO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and
- 2y agoGPCRStructure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development OfficerGlobeNewswireSAN FRANCISCO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and
- 2y agoGPCRStructure Therapeutics Appoints Angus C. Russell to Board of DirectorsGlobeNewswireSAN FRANCISCO, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and
- 2y agoGPCRStructure Therapeutics Announces Participation in Upcoming Investor ConferencesGlobeNewswireSAN FRANCISCO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and
- 2y agoGPCRStructure Therapeutics Reports Second Quarter 2024 Financial Results and Recent HighlightsGlobeNewswireGSBR-1290 Phase 2b study in obesity on track to initiate in the fourth quarter of 2024 Oral small molecule amylin receptor agonist development candidate expected to be selected in the fourth quarter of 2024 Obesity
- 2y agoGPCRStructure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary SharesGlobeNewswireSAN FRANCISCO, June 07, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and
- 2y agoGPCRStructure Therapeutics Announces Pricing of Upsized $476 Million Public OfferingGlobeNewswireSAN FRANCISCO, June 05, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and
- 2y agoGPCRZLABSDGRBILI+1Qiming's Nisa Leung Made the 2024 Forbes Midas ListPR NewswireThe 2024 Forbes Midas List, a distinguished industry list of the world's best venture capital investors, has been unveiled. Nisa Leung, Managing...
- 2y agoGPCRZLABSDGRBILI+1Qiming's Nisa Leung Made the 2024 Forbes Midas ListPR NewswireThe 2024 Forbes Midas List, a distinguished industry list of the world's best venture capital investors, has been unveiled. Nisa Leung, Managing...
- 2y agoGPCRStructure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded WarrantsGlobeNewswireSAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and
- 2y agoGPCRStructure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290GlobeNewswireGSBR-1290 achieved a clinically meaningful and statistically significant placebo-adjusted mean weight loss of 6.2% (p<0.0001) in the Phase 2a obesity study and up to 6.9% (p<0.0001) in the capsule to tablet PK
- 2y agoGPCRStructure Therapeutics Reports First Quarter 2024 Financial Results and Recent HighlightsGlobeNewswireTopline GSBR-1290 Phase 2a 12-week obesity data on track for June 2024 Phase 2b study in obesity expected to begin as planned in the fourth quarter 2024 Plan to initiate dosing in first-in-human Phase 1 clinical trial
- 2y agoGPCRStructure Therapeutics to Present at Leerink Partners Global Biopharma ConferenceGlobeNewswireSAN FRANCISCO, March 08, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and
- 2y agoGPCRStructure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent HighlightsGlobeNewswireTopline GSBR-1290 Phase 2a 12-week obesity data, as well as data from formulation bridging and titration optimization study, on track for latter half of the second quarter 2024 Phase 2b study in obesity expected to